SearchDictionaryMobileLogin

Ernesto L Schiffrin Selected Research

Hypertension (High Blood Pressure)

09/2008Role of endothelin-1 in clinical hypertension: 20 years on.
08/2008The flame that lights the fire: oxidative stress, inflammation, and renal damage in angiotensin II-induced hypertension.
06/2008Reactive oxygen species and hypertension: a complex association.
03/2008[New treatments in hypertension: direct renin inhibitors]
08/2007PPAR activation: a new target for the treatment of hypertension.
07/2007Novel drugs targeting hypertension: renin inhibitors and beyond.
04/2007Resistance artery remodeling in deoxycorticosterone acetate-salt hypertension is dependent on vascular inflammation: evidence from m-CSF-deficient mice.
07/2006Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension.
06/2005Vascular endothelin in hypertension.
01/2005Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: Effect of angiotensin II and role of insulinlike growth factor-1 receptor transactivation.
01/2005Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.
05/2004SAM68: a downstream target of angiotensin II signaling in vascular smooth muscle cells in genetic hypertension.
03/2004Endothelin-aldosterone interaction and proteinuria in low-renin hypertension.
01/2004Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin.
11/2003Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension.
10/2003Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
10/2003ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension.
10/2003Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension.
10/2003Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.
09/2003Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
08/2003Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice.
06/2003Role of endothelin in human hypertension.
06/2003Role of endothelins in animal models of hypertension: focus on cardiovascular protection.
04/2003Role of endothelin-1 in hypertension.
01/2003Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
08/2002Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension.
05/2002Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension.
05/2002Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
01/2002Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats.

Articles by Research Topic

Disease

29Hypertension (High Blood Pressure)
09/2008 - 01/2002
12Inflammation
08/2008 - 02/2002
8Stroke (Strokes)
12/2006 - 01/2002
7Fibrosis (Cirrhosis)
11/2005 - 02/2002
3Hypertrophy
11/2005 - 02/2002
1Cardiomegaly (Heart Hypertrophy)
10/2008
1Heart Failure
03/2008
1Hyperglycemia
06/2007
1Hyperaldosteronism (Conn Syndrome)
02/2005
1Tissue Adhesions
04/2004
1Diabetes Complications
04/2004
1Proteinuria
03/2004
1Vascular Diseases (Vascular Disease)
02/2003
1Diabetic Nephropathies (Diabetic Nephropathy)
03/2002

Drug/Important Bio-Agent (IBA)

15Angiotensin IIIBA
08/2008 - 05/2002
7Endothelins (Endothelin)IBA
06/2005 - 01/2003
6AldosteroneIBA
03/2008 - 02/2002
5Endothelin-1 (Endothelin 1)IBA
09/2008 - 02/2002
5Desoxycorticosterone (DOCA)FDA Link
04/2007 - 02/2002
4PPAR alphaIBA
02/2004 - 12/2002
3ReninIBA
03/2008 - 03/2004
3PPAR gammaIBA
06/2007 - 05/2002
3AngiotensinsIBA
10/2005 - 03/2002
2Reactive Oxygen Species (Oxygen Radicals)IBA
06/2008 - 05/2003
2Peroxisome Proliferator-Activated Receptors (PPAR)IBA
08/2007 - 10/2003
2Macrophage Colony-Stimulating FactorIBA
04/2007 - 10/2005
2Nitric Oxide (Nitrogen Monoxide)FDA Link
12/2006 - 04/2004
2PerindoprilFDA Link
09/2005 - 02/2002
2NADPH Oxidase (NAD(P)H oxidase)IBA
01/2005 - 05/2003
1ThioredoxinsIBA
10/2008
1Insulin (Novolin)FDA Link
06/2007
1Protein Kinases (Protein Kinase)IBA
12/2006
1rho-Associated KinasesIBA
05/2005
1Type 2 Angiotensin ReceptorIBA
05/2005
1MagnesiumIBA
02/2005
1CalciumIBA
02/2005
1Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
02/2005
1Neprilysin (Neutral Endopeptidase)IBA
02/2005
1pioglitazone (Actos)FDA Link
11/2004
1eplerenone (Inspra)FDA LinkGeneric
06/2004
1Procetofen (CiL)FDA LinkGeneric
02/2004
1PeptidesIBA
01/2004
1Natriuretic PeptidesIBA
01/2004
1LeptinIBA
01/2004
1AdrenomedullinIBA
01/2004
1Follicle Stimulating Hormone (Follitropin)IBA
10/2003
1Superoxides (Superoxide)IBA
10/2003
1Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA
08/2003
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
08/2002
1CollagenIBA
06/2002
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
06/2002
1Endothelin A ReceptorIBA
06/2002
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2002
1Matrix MetalloproteinasesIBA
02/2002
1Superoxide DismutaseIBA
01/2002